MA29849B1 - Composes exercant une activite au niveau du recepteur m1 et leurs utilisations en medecine - Google Patents

Composes exercant une activite au niveau du recepteur m1 et leurs utilisations en medecine

Info

Publication number
MA29849B1
MA29849B1 MA30812A MA30812A MA29849B1 MA 29849 B1 MA29849 B1 MA 29849B1 MA 30812 A MA30812 A MA 30812A MA 30812 A MA30812 A MA 30812A MA 29849 B1 MA29849 B1 MA 29849B1
Authority
MA
Morocco
Prior art keywords
compounds
medicine
alkyl
activity
substituted
Prior art date
Application number
MA30812A
Other languages
English (en)
Inventor
Brian Budzik
David Gwyn Cooper
Ian Thomson Forbes
Vincenzo Garzya
Jian Jin
Dongchuan Shi
Paul William Smith
Graham Walker
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0519950.0A external-priority patent/GB0519950D0/en
Priority claimed from GB0602040A external-priority patent/GB0602040D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA29849B1 publication Critical patent/MA29849B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Composés ayant une activité au niveau du récepteur M1 et leurs utilisations en médecine Des composés qui présentent une activité au niveau du récepteur M1 et leurs utilisations en médecine. Il est proposé des composés de formule (I) et leurs sels et produits de solvatation : formule dans laquelle R4 représente un groupe fluoro, R5 est choisi entre un atome d'hydrogène et un atome d'halogène, des groupes cyano, alkyle en C1 à C6, alkyle en C1 à C6 substitué avec un ou plusieurs atomes de fluor, alkoxy en C1 à C6 et alkoxy en C1 à C6 substitué avec un ou plusieurs atomes de fluor ; et R6 est choisi entre un atome d'halogène, un groupe cyano, alkyle en C1 à C6, alkyle en C1 à C6 substitué avec un ou plusieurs atomes de fluor cycloalkyle en C3 à C6, cycloalkyle en C3 à C6 substitué avec un ou plusieurs atomes de fluor, alkoxy en C1 à C6 et alkoxy en C1 à C6 substitué avec un ou plusieurs atomes de fluor et Q représente un atome d'hydrogène ou un groupe alkyle en C1 à C6. Il est prévu que les composés soient utiles en thérapie, par exemple dans le traitement de troubles psychotiques et d'une altération cognitive.
MA30812A 2005-09-30 2008-04-04 Composes exercant une activite au niveau du recepteur m1 et leurs utilisations en medecine MA29849B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0519950.0A GB0519950D0 (en) 2005-09-30 2005-09-30 Compounds
GB0602040A GB0602040D0 (en) 2006-02-01 2006-02-01 Compounds

Publications (1)

Publication Number Publication Date
MA29849B1 true MA29849B1 (fr) 2008-10-03

Family

ID=37598231

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30812A MA29849B1 (fr) 2005-09-30 2008-04-04 Composes exercant une activite au niveau du recepteur m1 et leurs utilisations en medecine

Country Status (24)

Country Link
US (2) US8283364B2 (fr)
EP (1) EP1943230B1 (fr)
JP (1) JP5209480B2 (fr)
KR (2) KR20130091791A (fr)
CN (1) CN101321736B (fr)
AR (1) AR056103A1 (fr)
AT (1) ATE492537T1 (fr)
AU (1) AU2006296369B2 (fr)
BR (1) BRPI0616609A2 (fr)
CA (1) CA2624504C (fr)
CR (1) CR9904A (fr)
DE (1) DE602006019119D1 (fr)
EA (1) EA016286B1 (fr)
IL (1) IL190219A (fr)
JO (1) JO2634B1 (fr)
MA (1) MA29849B1 (fr)
MY (1) MY148504A (fr)
NO (1) NO20081945L (fr)
NZ (1) NZ566508A (fr)
PE (1) PE20070490A1 (fr)
TW (1) TWI389905B (fr)
UA (1) UA101299C2 (fr)
WO (1) WO2007036715A2 (fr)
ZA (1) ZA200802167B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1960389B1 (fr) * 2005-09-30 2012-08-15 Glaxo Group Limited Composes exerçant une activite au niveau du recepteur m1 et leurs utilisations en medecine
US8283364B2 (en) 2005-09-30 2012-10-09 Glaxo Group Limited Compounds which have activity at M1 receptor and their uses in medicine
US8288413B2 (en) * 2005-09-30 2012-10-16 Glaxo Group Limited Benzimidazolones which have activity at M1 receptor
US7766829B2 (en) * 2005-11-04 2010-08-03 Abbott Diabetes Care Inc. Method and system for providing basal profile modification in analyte monitoring and management systems
GB0605785D0 (en) * 2006-03-22 2006-05-03 Glaxo Group Ltd Compounds
GB0706170D0 (en) * 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706164D0 (en) * 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706174D0 (en) * 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706165D0 (en) * 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0718415D0 (en) * 2007-09-20 2007-10-31 Glaxo Group Ltd Compounds
WO2009124882A1 (fr) * 2008-04-09 2009-10-15 H. Lundbeck A/S Nouvelles pipéridinyl-1,3-dihydrobenzoimidazol-2-ones comme agonistes de m1
GB0817982D0 (en) 2008-10-01 2008-11-05 Glaxo Group Ltd Compounds
JP2017533227A (ja) * 2014-11-03 2017-11-09 ウィリアム・ボーモント・ホスピタルＷｉｌｌｉａｍ Ｂｅａｕｍｏｎｔ Ｈｏｓｐｉｔａｌ 低活動膀胱症候群を治療するための方法
TWI706952B (zh) 2015-04-29 2020-10-11 比商健生藥品公司 氮雜苯并咪唑類及其作為ａｍｐａ受體調控劑之用途
BR112017023200A2 (pt) * 2015-04-29 2018-08-07 Janssen Pharmaceutica Nv compostos de indolona e seu uso como moduladores do receptor de ampa
WO2017044693A1 (fr) 2015-09-11 2017-03-16 Chase Pharmaceuticals Corporation Combinaison muscarinique et son utilisation pour lutter contre des troubles hypocholinergiques du système nerveux central
CN107673994A (zh) * 2017-04-27 2018-02-09 联化科技股份有限公司 一种芳基甲烷类化合物的制备方法
CN107739342B (zh) * 2017-11-29 2020-01-10 华南理工大学 一种一步合成5-二芳氨基苯并咪唑酮衍生物的方法
CN117049938A (zh) * 2023-06-20 2023-11-14 山东轩德医药科技有限公司 一种6-溴-2,3-二氟甲苯的制备方法

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3161645A (en) * 1962-12-18 1964-12-15 Res Lab Dr C Janssen N V 1-(1-aroylpropyl-4-piperidyl)-2-benzimidazolinones and related compounds
US3989707A (en) * 1974-06-21 1976-11-02 Janssen Pharmaceutica N.V. Benzimidazolinone derivatives
US4292321A (en) * 1979-05-24 1981-09-29 Warner-Lambert Company 1,3,8-Triazaspirodecane-4-ones, pharmaceutical compositions thereof and method of use thereof
DE3124366A1 (de) 1981-06-20 1982-12-30 Hoechst Ag, 6000 Frankfurt N-oxacyclyl-alkylpiperidin-derivate, verfahren zu ihrer herstellung, sie enthaltende pharmazeutische praeparate und deren verwendung
DE4040300A1 (de) 1990-12-17 1992-07-02 Leifeld Gmbh & Co Drueckmaschine mit wenigstens einem rollenhalter
JP3916093B2 (ja) * 1993-09-17 2007-05-16 杏林製薬株式会社 光学活性イミダゾリジノン誘導体とその製造方法
EP0786997A4 (fr) * 1994-10-27 1998-03-11 Merck & Co Inc Antagonistes de muscarine
US5691323A (en) * 1995-05-12 1997-11-25 Merck & Co., Inc. Muscarine antagonists
US5574044A (en) * 1994-10-27 1996-11-12 Merck & Co., Inc. Muscarine antagonists
AU7478396A (en) 1995-10-31 1997-05-22 Merck & Co., Inc. Muscarine agonists
US5718912A (en) * 1996-10-28 1998-02-17 Merck & Co., Inc. Muscarine agonists
US5977134A (en) * 1996-12-05 1999-11-02 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6465484B1 (en) * 1997-09-26 2002-10-15 Merck & Co., Inc. Angiogenesis inhibitors
US6162804A (en) * 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
WO1999032481A1 (fr) * 1997-12-23 1999-07-01 Alcon Laboratories, Inc. Agents muscariniques et leur utilisation pour traiter le glaucome, la myopie, et d'autres dysfonctionnements
WO2001027104A1 (fr) 1999-10-13 2001-04-19 Banyu Pharmaceutical Co., Ltd. Derives d'imidazolidinone a substitution
SE9904652D0 (sv) * 1999-12-17 1999-12-17 Astra Pharma Prod Novel Compounds
WO2001057019A1 (fr) * 2000-02-01 2001-08-09 Cor Therapeutics, Inc. INHIBITEURS INDALONE ET BENZIMIDAZOLONE DU FACTEUR Xa
EP1385518B1 (fr) * 2001-04-18 2008-08-06 Euro-Celtique S.A. Composes de benzimidazolone
EP1386920A4 (fr) 2001-04-20 2005-09-14 Banyu Pharma Co Ltd Derives de benzimidazolone
US6951849B2 (en) * 2001-10-02 2005-10-04 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
CA2457647A1 (fr) * 2001-10-02 2003-04-10 Acadia Pharmaceuticals, Inc. Derives de benzimidazolidinone utilises comme agents muscariniques
WO2004089942A2 (fr) 2001-10-02 2004-10-21 Acadia Pharmaceuticals Inc. Derives de benzimidazolidinone utilises en tant qu'agents muscariniques
WO2003037890A2 (fr) * 2001-11-01 2003-05-08 Icagen, Inc. Piperidines
DK1491212T3 (da) 2002-03-29 2012-10-29 Mitsubishi Tanabe Pharma Corp Middel til behandling af søvnforstyrrelser
CA2488845A1 (fr) 2002-06-17 2003-12-24 Merck & Co., Inc. Compositions ophtalmiques destinees a traiter l'hypertension oculaire
US7645771B2 (en) 2002-12-13 2010-01-12 Smithkline Beecham Corp. CCR5 antagonists as therapeutic agents
JP2005102133A (ja) 2003-04-28 2005-04-14 Ricoh Co Ltd 画像形成装置及び宛先情報参照方法
JP2006528186A (ja) * 2003-07-23 2006-12-14 ワイス ５−ヒドロキシトリプタミン−６リガンドとしてのスルホニルジヒドロベンゾイミダゾロン化合物
PL1664036T3 (pl) * 2003-09-03 2012-04-30 Pfizer Związki benzimidazolonu wykazujące działanie agonistyczne względem receptora 5-ht4
ES2318556T3 (es) * 2004-11-02 2009-05-01 Pfizer, Inc. Derivados de sulfonil bencimidazol.
US7300947B2 (en) * 2005-07-13 2007-11-27 Banyu Pharmaceutical Co., Ltd. N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives
EP1960389B1 (fr) 2005-09-30 2012-08-15 Glaxo Group Limited Composes exerçant une activite au niveau du recepteur m1 et leurs utilisations en medecine
US8288413B2 (en) * 2005-09-30 2012-10-16 Glaxo Group Limited Benzimidazolones which have activity at M1 receptor
US8283364B2 (en) 2005-09-30 2012-10-09 Glaxo Group Limited Compounds which have activity at M1 receptor and their uses in medicine
US8239995B2 (en) 2006-09-08 2012-08-14 The Gillette Company Toothbrush with multiple bristles states
GB0706188D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706189D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706165D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706167D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706174D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706164D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706173D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706190D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706168D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706187D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706170D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
CA2624504C (fr) 2014-07-08
ATE492537T1 (de) 2011-01-15
US8283364B2 (en) 2012-10-09
DE602006019119D1 (de) 2011-02-03
CR9904A (es) 2008-07-29
EP1943230B1 (fr) 2010-12-22
WO2007036715A3 (fr) 2007-05-18
IL190219A (en) 2012-10-31
EA200801001A1 (ru) 2008-08-29
JP2009512635A (ja) 2009-03-26
MY148504A (en) 2013-04-30
EA016286B1 (ru) 2012-03-30
TWI389905B (zh) 2013-03-21
PE20070490A1 (es) 2007-05-30
CA2624504A1 (fr) 2007-04-05
BRPI0616609A2 (pt) 2011-06-28
EP1943230A2 (fr) 2008-07-16
NO20081945L (no) 2008-06-04
JO2634B1 (en) 2012-06-17
UA101299C2 (uk) 2013-03-25
JP5209480B2 (ja) 2013-06-12
AU2006296369B2 (en) 2012-12-20
ZA200802167B (en) 2009-08-26
AU2006296369A1 (en) 2007-04-05
US8481566B2 (en) 2013-07-09
NZ566508A (en) 2011-07-29
KR101374458B1 (ko) 2014-03-17
WO2007036715A2 (fr) 2007-04-05
US20080058378A1 (en) 2008-03-06
CN101321736B (zh) 2012-04-04
CN101321736A (zh) 2008-12-10
TW200806657A (en) 2008-02-01
KR20130091791A (ko) 2013-08-19
AR056103A1 (es) 2007-09-19
IL190219A0 (en) 2008-11-03
KR20080049090A (ko) 2008-06-03
US20080255195A1 (en) 2008-10-16

Similar Documents

Publication Publication Date Title
MA29849B1 (fr) Composes exercant une activite au niveau du recepteur m1 et leurs utilisations en medecine
CA2662848C (fr) Derives de 2-aryl-6-phenyl-imidazo[1,2-.alpha.]pyridines, leur preparation et leur application en therapeutique
MA27390A1 (fr) Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique
MA28422B1 (fr) Derives de n- (1,5-diphenyl-1h-pyrazol-3-yl) sulfonamide avec une affinite pour les recepteurs cb1
MA30324B1 (fr) Benzimidazoles presentant une activite au niveau du recepteur m1 et leurs utilisations en medecine.
CA2481461A1 (fr) Derives de n-[phenyl(piperidin-2-yl) methyl] benzamide, leur preparation et leur application en therapeutique
MA27448A1 (fr) Derives de pyridine modulateurs du recepteur cb2
MA26989A1 (fr) Derives de pyridine inhibiteurs de metalloproteinases de matrice
TNSN06358A1 (fr) Methyl-aryl-ou-heteroaryl-amides substitues
MA31865B1 (fr) Dérivés isoxazolo-pyridine
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
TNSN07253A1 (fr) Derives de n- (heteroaryl) -1h-indole-2-carboxamides et leur utilisation comme ligands du recepteur vanilloide trpv1
RU2006130466A (ru) Аминоспирт
MA30073B1 (fr) Derives de piperidine 3,5-substitues en tant qu'inhibiteurs de renine
MA27747A1 (fr) Dérivés azabicycliques à substituants pyridyloxyméthyle et benzisoxazole
MA30014B1 (fr) Derives spirocycliques
MA33893B1 (fr) Derives de diphenyl-pyrazolopyridines,leur preparation et leur appalication en therapeutique
TNSN07145A1 (fr) Derives de 2-amido-4-phenylthiazole, leur preparation et leur application en therapeutique
BRPI0418074B8 (pt) derivado de amida, composição farmacêutica, inibidor da tirosina cinase bcr-abl e agentes terapêuticos
FR2856684A1 (fr) Derives de diphenylpyridine, leur preparation et leur application en therapeutique
TN2011000550A1 (fr) Derives de cyclopenta[c] pyrrolyla lkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique
CA2171675A1 (fr) Composes heterocycliques aromatiques, compositions pharmaceutiques et cosmetiques les contenant et utilisations
MA31742B1 (fr) Derives de l'indol-2-one disubstitues en 3, leur preparation et leur application en therapeutique
MA29559B1 (fr) Derives de 4,5-diarylpyrrole, leur preparation et leur application en therapeutique
FR2870541A1 (fr) Derives de pyrimidines antigonistes du recepteur de la vitronectine